Disseminated intravascular coagulation – new pathophysiological concepts and impact on management

References

• Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haesmost. 1980;43:28–33.
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr., Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330.
   PubMed Web of Science ®Google Scholar
• Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British committee for standards in haematology. Br J Haematol. 2009 Apr;145(1):24–33.
   PubMed Web of Science ®Google Scholar
• ten Cate H, Schoenmakers SH, Franco R, et al. Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med. 2001;29(7 Suppl):S95–S97.
   PubMed Web of Science ®Google Scholar
• Thachil J, Falanga A, Levi M, et al. Scientific and standardization committee of the international society on thrombosis and hemostasis. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(4):671–675.
   PubMed Web of Science ®Google Scholar
• Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol. 2015;213(4):452–463.
   PubMed Web of Science ®Google Scholar
• Østerud B, Bjørklid E. Sources of tissue factor. Semin Thromb Hemost. 2006;32:11–23.
   PubMed Web of Science ®Google Scholar
• Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125(Suppl 1):S70–S73.
   PubMed Web of Science ®Google Scholar
• Gando S, Nanzaki S, Sasaki S, et al. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost. 1998;79:1111–1115.
   PubMed Web of Science ®Google Scholar
• Levi M. Management of cancer-associated disseminated intravascular coagulation. Thromb Res. 2016;140(Suppl 1):S66–S70.
   PubMed Web of Science ®Google Scholar
• Wang J-G, Manly D, Kirchhofer D, et al. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost. 2009;7:1092–1098.
   PubMed Web of Science ®Google Scholar
• Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost. 2010 Nov;36(8):865–867.
   PubMed Web of Science ®Google Scholar
• Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intensive Care. 2015 Jan 7;3(1):2.
   PubMed Web of Science ®Google Scholar
• Sandset PM, Warn-Cramer BJ, Rao VML, et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiological role of EPI as a natural anticoagulant. Proc Natl Acad Sci U S A. 1991;88:708–712.
   PubMed Web of Science ®Google Scholar
• Tang H, Ivanciu L, Popescu N, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol. 2007;171:1066–1077.
   PubMed Web of Science ®Google Scholar
• de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor (TFPI) dose dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000;95:1124–1129.
   PubMed Web of Science ®Google Scholar
• Esmon CT. Protein C anticoagulant system–anti-inflammatory effects. Semin Immunopathol. 2012 Jan;34(1):127–3.
   PubMed Web of Science ®Google Scholar
• Levi M. Activated protein C in sepsis: a critical review. Curr Opin Hematol. 2008 Sep;15(5):481–486.
   PubMed Web of Science ®Google Scholar
• Levi M, Dörffler-Melly J, Reitsma P, et al. Aggravation of endotoxin induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003;101:4823–4827.
   PubMed Web of Science ®Google Scholar
• Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345:408–416.
   PubMed Web of Science ®Google Scholar
• Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007;245:812–818.
   PubMed Web of Science ®Google Scholar
• Yanagida Y, Gando S, Sawamura A, et al. Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. Surgery. 2013;154(1):48–57.
   PubMed Web of Science ®Google Scholar
• Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64:1211–1217.
   PubMedGoogle Scholar
• Gando S, Wada H, Thachil J. Scientific standardization committee on DIC ISTH: differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost. 2013;11:826–835.
   PubMed Web of Science ®Google Scholar
• Levy JH, Sniecinski RM, Welsby IJ, et al. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016 Apr 1;115(4):712–728.
   PubMed Web of Science ®Google Scholar
• Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med. 2000;28:S34–S37.
   PubMed Web of Science ®Google Scholar
• Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000;95:1117–1123.
   PubMed Web of Science ®Google Scholar
• Leitner JM, Firbas C, Mayr FB, et al. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther. 2006;79:23–34.
   PubMed Web of Science ®Google Scholar
• Ostrovsky L, Woodman RC, Payne D, et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 1997;96:2302–2310.
   PubMed Web of Science ®Google Scholar
• Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost. 2009;7(1):4–13.
   PubMed Web of Science ®Google Scholar
• Pralong G, Calandra T, Glauser MP, et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost. 1989;61(3):459–462.
   PubMed Web of Science ®Google Scholar
• Mesters RM, Flörke N, Ostermann H, et al. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost. 1996;75(6):902–907.
   PubMed Web of Science ®Google Scholar
• Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84(5):398–405 37.
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Sawamura A, Gando S, et al. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res. 2012;130(6):906–913.
   PubMed Web of Science ®Google Scholar
• Zeerleder S, Schroeder V, Hack CE, et al. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006;118(2):205–212.
   PubMed Web of Science ®Google Scholar
• Emonts M, de Bruijne ELE, Guimarães AHC, et al. Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost. 2008;6(2):268–276.
   PubMed Web of Science ®Google Scholar
• Raza I, Davenport R, Rourke C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11:307–314.
   PubMed Web of Science ®Google Scholar
• Cotton BA, Harvin JA, Kostousouv V, et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg. 2012;73:365–370.
   PubMed Web of Science ®Google Scholar
• Cardenas JC, Matijevic N, Baer LA, et al. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock. 2014;41:514–521.
   PubMed Web of Science ®Google Scholar
• Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest. 2005;115:1267–1274.
   PubMed Web of Science ®Google Scholar
• Nesheim M, Wang W, Boffa M, et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997 Jul;78(1):386–391.
   PubMed Web of Science ®Google Scholar
• Wang H, Vinnikov I, Shahzad K, et al. The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition. Thromb Haemost. 2012;108:1141–1153.
   PubMed Web of Science ®Google Scholar
• Nakahara M, Ito T, Kawahara K, et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One. 2013;8:e7596.
   Web of Science ®Google Scholar
• Ito T, Maruyama I. Thrombomodulin: protectorate god of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011 Jul;9(Suppl 1):168–7.
   PubMed Web of Science ®Google Scholar
• Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Archiv Eur J Physiol. 2007;454:345–359.
   PubMed Web of Science ®Google Scholar
• Chelazzi C, Villa G, Mancinelli P, et al. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015 Jan 28;19:26.
   PubMed Web of Science ®Google Scholar
• Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res. 2009 Jul 15;83(2):388–396.
   PubMed Web of Science ®Google Scholar
• Marechal X, Favory R, Joulin O, et al. Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock. 2008;29:572–576.
   PubMed Web of Science ®Google Scholar
• Nieuwdorp M, Meuwese MC, Mooij HL, et al. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis. 2009;202:296–303.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg. 2012;73:60–66.
   PubMed Web of Science ®Google Scholar
• Johansson PI, Stensballe J, Rasmussen LS, et al. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254:194–200.
   PubMed Web of Science ®Google Scholar
• Liaw PC, Ito T, Iba T, et al. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev. 2015 Dec 31. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009 Nov;15(11):1318–1321.
   PubMed Web of Science ®Google Scholar
• Kim J-E, Lee N, Gu J-Y, et al. Circulating levels of DNA-histone complex and dsDNA are independent prognostic factors of disseminated intravascular coagulation. Thromb Res. 2015 Jun;135(6):1064–1069.
   PubMed Web of Science ®Google Scholar
• Abrams ST, Zhang N, Manson J, et al. Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med. 2013;187:160–169.
   PubMed Web of Science ®Google Scholar
• Nakahara M, Ito T, Kawahara KI, et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One. 2013;8:e75961.
   PubMed Web of Science ®Google Scholar
• Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007;104:6388–6393.
   PubMed Web of Science ®Google Scholar
• Dwivedi DJ, Toltl LJ, Swystun LL, et al. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care. 2012;16:R151.
   PubMed Web of Science ®Google Scholar
• Longstaff C, Varjú I, Sótonyi P, et al. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem. 2013 Mar 8;288(10):6946–6956.
   PubMed Web of Science ®Google Scholar
• Okajima K. The role of leukocytes in disseminated intravascular coagulation associated with sepsis. Sepsis. 1999;3:135–142.
   Google Scholar
• Bouchard BA, Tracy PB. The participation of leukocytes in coagulant reactions. J Thromb Haemost. 2003 Mar;1(3):464–469.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol. 2007 Aug;5(8):577–582.
   PubMed Web of Science ®Google Scholar
• Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood. 2014;123(18):2768–2776.
   PubMed Web of Science ®Google Scholar
• Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107:15880–15885.
   PubMed Web of Science ®Google Scholar
• Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13:463–469.
   PubMed Web of Science ®Google Scholar
• Gould TJ, Vu TT, Swystun LL, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1977–1984.
   PubMed Web of Science ®Google Scholar
• Whelihan MF, Mann KG. The role of the red cell membrane in thrombin generation. Thromb Res. 2013 May;131(5):377–382.
   PubMed Web of Science ®Google Scholar
• Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–4996.
   PubMed Web of Science ®Google Scholar
• Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol. 2013 Sep;20(5):472–477.
   PubMed Web of Science ®Google Scholar
• Moore HB, Moore EE, Gonzalez E, et al. Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury. Shock. 2015;43:39–46.
   PubMed Web of Science ®Google Scholar
• van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:639–651.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–342.
   PubMed Web of Science ®Google Scholar
• Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162.
   PubMed Web of Science ®Google Scholar
• Ito T, Kawahara K, Nakamura T, et al. High mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007;5:109–116.
   PubMed Web of Science ®Google Scholar
• Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94:975–979.
   PubMed Web of Science ®Google Scholar
• Morrissey JH, Smith SA. Polyphosphate as modulator of hemostasis, thrombosis, and inflammation. J Thromb Haemost. 2015;13(Suppl 1):S92–S97.
   PubMed Web of Science ®Google Scholar
• Wat JM, Foley JH, Krisinger MJ, et al. Polyphosphate suppresses complement via the terminal pathway. Blood. 2014 Jan 30;123(5):768–776.
   PubMed Web of Science ®Google Scholar
• Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost. 2015;13(Suppl. 1):S121–S32.
   PubMed Web of Science ®Google Scholar
• Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177:4794–4802.
   PubMed Web of Science ®Google Scholar
• Lupu F, Keshari RS, Lambris JD, et al. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res. 2014 May;133(Suppl 1):S28–S31.
   PubMed Web of Science ®Google Scholar
• Gould TJ, Lysov Z, Liaw PC. Extracellular DNA and histones: double-edged swords in immunothrombosis. J Thromb Haemost. 2015 Jun;13(Suppl 1):S82–S91.
   PubMed Web of Science ®Google Scholar
• Gando S, Otomo Y. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care. 2015 Feb 23;19:72.
   PubMed Web of Science ®Google Scholar
• Wada H, Thachil J, Di Nisio M, et al. The scientific standardization committee on DIC of the international society on thrombosis haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761–767. doi:10.1111/jth.12155
   Google Scholar
• Iba T, Ito T, Maruyama I, et al. Potential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Rev. 2016 Mar;30(2):149–155.
   PubMed Web of Science ®Google Scholar
• Bakhtiari K, Meijers JC, de Jonge E, et al. Prospective validation of the international society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004 Dec;32(12):2416–2421.
   PubMed Web of Science ®Google Scholar
• Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the international society of thrombosis and hemostasis and of the Japanese ministry of health and welfare for overt DIC. Am J Hematol. 2003 Sep;74(1):17–22.
   PubMed Web of Science ®Google Scholar
• Kaneko T, Wada H. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop. 2011;51(2):67–76.
   PubMedGoogle Scholar
• Grottke O, Braunschweig T, Spronk HM, et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood. 2011 Aug 18;118(7):1943–1951.
   PubMed Web of Science ®Google Scholar
• Liu X-L, Wang X-Z, Liu X-X, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study. Exp Ther Med. 2014 Mar;7(3):604–608.
   PubMed Web of Science ®Google Scholar
• Sakuragawa N, Hasegawa H, Maki M, et al. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)–a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 1993 Dec 15;72(6):475–500.
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.
   PubMed Web of Science ®Google Scholar
• Dhainaut J-F, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924–1933.
   PubMed Web of Science ®Google Scholar
• Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–2064.
   PubMed Web of Science ®Google Scholar
• Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis. 2012;12:678–686.
   PubMed Web of Science ®Google Scholar
• Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016 Mar;103(3):253–261.
   PubMed Web of Science ®Google Scholar
• Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–1878.
   PubMed Web of Science ®Google Scholar
• Iba T, Kidokoro A. High dose antithrombin therapy for sepsis: mechanism of action. Shock. 2002;18:389–394.
   PubMed Web of Science ®Google Scholar
• Iba T, Saitoh D. Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation. J Intensive Care. 2014;2:66.
   PubMedGoogle Scholar
• Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:R297.
   PubMed Web of Science ®Google Scholar
• Iba T, Saitoh D, Gando S, et al. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2015;135:897–901.
   PubMed Web of Science ®Google Scholar
• Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Horiguchi H, et al. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2015;13:31–40.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Fushimi K, et al. Use of recombinant human soluble thrombomodulin in patients with sepsisinduced disseminated intravascular coagulation after intestinal perforation. Font Med. 2015;2:1–7.
   PubMedGoogle Scholar
• Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:508–519.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069–2079.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Thachil J, Squizzato A. Management of disseminated intravascular coagulation: a survey of the international society on thrombosis and haemostasis. Thromb Res. 2015 Aug;136(2):239–242.
   PubMed Web of Science ®Google Scholar